Mivebresib (ABBV-075), also known as ABBV-075, is a potent BET inhibitor (bromodomain (BRD)-containing protein) with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins.
Molecular Weight:
459.47
Purity:
97.17%
CAS Number:
[1445993-26-9]
Formula:
C22H19F2N3O4S
Target:
Epigenetic Reader Domain|||Apoptosis
T3712
* VAT and and shipping costs not included. Errors and price changes excepted
